Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

NCT06493552 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle-Invasive Bladder Carcinoma
Metastatic Urothelial Carcinoma

Interventions

DRUG: SEphB4-HSA
DRUG: Pembrolizumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Enfortumab vedotin

Sponsor

Vasgene Therapeutics, Inc